Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309204 | 1.00 | CCNT1 (0.41) | CCNT1CDK9ALDH1A1NR1H2NR1H3 | |
| SCHEMBL29889444 | 1.00 | CCNT1 (0.41) | CCNT1CDK9ALDH1A1NR1H2NR1H3 | |
| SCHEMBL29524293 | 0.99 | CCNT1 (0.41) | CCNT1CDK9ALDH1A1NR1H2NR1H3 | |
| SCHEMBL6536648 | 0.99 | CCNT1 (0.41) | CCNT1CDK9ALDH1A1NR1H2NR1H3 | |
| SCHEMBL22333707 | 0.88 | HSD17B10 (0.41) | ALDH1A1NR1H2NR1H3HPGDPTPN1 | |
| SCHEMBL15397259 | 0.87 | USP2 (0.44) | CCNT1CDK9NR1H2NR1H3AGTR2 | |
| SCHEMBL14915300 | 0.87 | USP2 (0.44) | CCNT1CDK9NR1H2NR1H3AGTR2 | |
| SCHEMBL4312766 | 0.86 | HSD17B10 (0.43) | AGTR2HPGDPREPHSD17B10CHRM2 | |
| SCHEMBL4312765 | 0.86 | HSD17B10 (0.43) | AGTR2HPGDPREPHSD17B10CHRM2 | |
| SCHEMBL4316869 | 0.86 | CCNT1 (0.40) | CCNT1CDK9ALDH1A1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866422-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2024-01-09 | — | — | US | disclosed |
| CN-109563033-B | Aliphatic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2016100555-A1 | BORONIC ACID DERIVATIVES AND USES THEREOF | INCEPTION 4, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| WO-2006115918-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | CCNT1 327/4885CDK9 1821/4885ALDH1A1 122/4885 |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | CCNT1 139/4885CDK9 1003/4885ALDH1A1 271/4885 |
| US-11866422-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | CCNT1 139/4885CDK9 1003/4885ALDH1A1 271/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | CCNT1 327/4885CDK9 1821/4885ALDH1A1 122/4885 |
| US-20090069376-A1 | VLA-4 Antagonists | VCAM1, SELPLG, ITGB4 | CCNT1 3334/4885CDK9 2231/4885ALDH1A1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.